Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adderall is a central nervous system (CNS) stimulant composed of a combination of four amphetamine salts: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate. It is primarily indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The medication works by increasing the levels of norepinephrine and dopamine in the synaptic cleft through the inhibition of reuptake and the promotion of release via the dopamine transporter (DAT) and norepinephrine transporter (NET). It also acts as an agonist at the trace amine-associated receptor 1 (TAAR1) and inhibits the vesicular monoamine transporter 2 (VMAT2). While widely used as a prescription medication, it was the subject of a Phase 4 clinical trial by the Mayo Clinic (NCT02979327) to evaluate its acute cardiovascular effects, such as changes in blood pressure and heart rate, in healthy adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adderall.